A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
Price : $35 *
At a glance
- Drugs Tesidolumab (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 15 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jan 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 May 2018 to 1 Jun 2015.